<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medalphabet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский алфавит</journal-title><trans-title-group xml:lang="en"><trans-title>Medical alphabet</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2078-5631</issn><issn pub-type="epub">2949-2807</issn><publisher><publisher-name>ООО «Альфмед»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33667/2078-5631-2020-20-42-45</article-id><article-id custom-type="elpub" pub-id-type="custom">medalphabet-1653</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group></article-categories><title-group><article-title>Клиническое применение сцинтиграфии и ОФЭКТ/КТ с препаратом 99тТс-Тектротид у пациентов с нейроэндокринными опухолями</article-title><trans-title-group xml:lang="en"><trans-title>Clinical utility of scintigraphy and SPECT/CT with 99m Tc-Tectrotyd in patients with neuroendocrine tumors</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каспшик</surname><given-names>С. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Kaspshik</surname><given-names>S. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Аспирант, врач-радиолог лаборатории радиоизотопной диагностики отдела радиоизотопной диагностики и терапии.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Долгушин</surname><given-names>М. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Dolgushin</surname><given-names>M. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доктор медицинских наук, профессор РАН, профессор кафедры Кафедра рентгенологии и радиологии РМАНПО, руководитель отдела радиоизотопной диагностики и терапии, зав. отделением - врач-радиолог позитронной эмиссионной томографии - и.о. зав. лабораторией – врача радиолога лаборатории радиоизотопной диагностики.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Артамонова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Artamonova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доктор медицинских наук, зав. отделением лекарственных методов лечения (химиотерапевтическое) № 1 НМИЦО им. Н.Н. Блохина, профессор кафедры Кафедра онкологии и лучевой терапии РНИМУ им. Н И. Пирогова, МОНИКИ им. М.Ф. Владимирского.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маркович</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Markovich</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кандидат медицинских наук, старший научный сотрудник научно-консультативного отделения.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рыжков</surname><given-names>А. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Ryzhkov</surname><given-names>A. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доктор медицинских наук, ведущий научный сотрудник лаборатории радиоизотопной диагностики отдела радиоизотопной диагностики и терапии.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Емельянова</surname><given-names>Г. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Emelyanova</surname><given-names>G. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ассистент кафедры онкологии ФДПО.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Билик</surname><given-names>М. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Bilik</surname><given-names>M. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Врач-радиолог лаборатории радиоизотопной диагностики отдела радиоизотопной диагностики и терапии.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Centre of Oncology n.a. N.N. Blokhin</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Минздрава России; Кафедра рентгенологии и радиологии ФГБОУ ДПО Российская медицинская академия непрерывного последипломного образования» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Centre of Oncology n.a. N.N. Blokhin; Russian Medical Academy of Post-Graduate Education</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Минздрава России; Кафедра онкологии и лучевой терапии ФГБОУ ВО «Российский национальный исследовательский медицинский университет имени Н. И. Пирогова» Минздрава России; Кафедра онкологии и торакальной хирургии ФУВ ГБУЗ МО Московский областной научно-исследовательский клинический институт им. М. Ф. Владимирского</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Centre of Oncology n.a. N.N. Blokhin; Russian National Research Medical University n.a. N.I. Pirogov; Moscow Regional Research Clinical Institute n.a. M.F. Vladimirsky</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ФГБОУ ВО «Московский государственный медико-стоматологический университет имени А. И. Евдокимова» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow State University of Medicine and Dentistry n.a. A.I. Evdokimov</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>10</day><month>10</month><year>2020</year></pub-date><volume>0</volume><issue>20</issue><issue-title>Диагностика и онкотерапия (2)</issue-title><fpage>42</fpage><lpage>45</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Каспшик С.М., Долгушин М.Б., Артамонова Е.В., Маркович А.А., Рыжков А.Д., Емельянова Г.С., Билик М.Е., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Каспшик С.М., Долгушин М.Б., Артамонова Е.В., Маркович А.А., Рыжков А.Д., Емельянова Г.С., Билик М.Е.</copyright-holder><copyright-holder xml:lang="en">Kaspshik S.M., Dolgushin M.B., Artamonova E.V., Markovich A.A., Ryzhkov A.D., Emelyanova G.S., Bilik M.E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-alphabet.com/jour/article/view/1653">https://www.med-alphabet.com/jour/article/view/1653</self-uri><abstract><p>Статья посвящена инновационному методу оцинтиграфии нейроэндокринных опухолей с 99тТс-Тектротидом. Это новый альтернативный и более доступный метод диагностики, позволяющий определять рецепторный статус опухоли, оценить распространенность опухолевого процесса и эффективность проведенного лечения. Данное исследование также может быть первым шагом к планированию радионуклидной терапии пациентов с нейроэндокринными опухолями. В статье представлены методика проведения исследования, интерпретация результатов на отдельных примерах и тераностический подход.</p></abstract><trans-abstract xml:lang="en"><p>This article describes a new affordable diagnostic method of neuroendocrine tumors, shows the basic information on it’s conduction and interpretation of the results. Scintigraphy of neuroendocrine tumors with 99mTc-Tectro-tyd is a new alternative and more affordable diagnostic method that allows you to determine tumor receptor status, assess the prevalence of the tumor process and plan therapy. This study may also be the first step in planning radionuclide therapy for patients with neuroendocrine tumors. Also there is a short review on teranostics.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>онкология</kwd><kwd>ядернаямедицина</kwd><kwd>нейроэндокринные опухоли</kwd><kwd>сцинтиграфия</kwd><kwd>тераностика</kwd></kwd-group><kwd-group xml:lang="en"><kwd>oncology</kwd><kwd>nuclear medicine</kwd><kwd>neuroendocrine tumors</kwd><kwd>scintigraphy</kwd><kwd>teranostics</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Plockinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS) Neuroendocrinology. 2004; 80: 394-424.</mixed-citation><mixed-citation xml:lang="en">Plockinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS) Neuroendocrinology. 2004; 80: 394-424.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Kwekkeboom DJ, Krenning EP, Lebtahi R, Kommi-noth P, Kos-Kudta B, de Herder WW, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology. 2009; 90: 220-6.</mixed-citation><mixed-citation xml:lang="en">Kwekkeboom DJ, Krenning EP, Lebtahi R, Kommi-noth P, Kos-Kudta B, de Herder WW, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology. 2009; 90: 220-6.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Oberg K, Castellano D. Current knowledge on diagnosis and staging of neuroendocrine tumors. Cancer Metastasis Rev. 20N; 30 (Suppl 1): 3-7.</mixed-citation><mixed-citation xml:lang="en">Oberg K, Castellano D. Current knowledge on diagnosis and staging of neuroendocrine tumors. Cancer Metastasis Rev. 20N; 30 (Suppl 1): 3-7.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Rothenstein J, Cleary SP, Pond GR, Dale D, Gallinger S, Moore MJ, et al. Neuroendocrine tumors of the gastrointestinal tract: A decade of experience at the princess margaret hospital. Am J Clin Oncol. 2008; 31: 64-70.</mixed-citation><mixed-citation xml:lang="en">Rothenstein J, Cleary SP, Pond GR, Dale D, Gallinger S, Moore MJ, et al. Neuroendocrine tumors of the gastrointestinal tract: A decade of experience at the princess margaret hospital. Am J Clin Oncol. 2008; 31: 64-70.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol. 1995; 13: 2094-103.</mixed-citation><mixed-citation xml:lang="en">Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol. 1995; 13: 2094-103.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Granberg D, Sundin A, Janson ET et al. Octreoscan in patients with bronchial carcinoid tumours. Clin Endocrinol (Oxf) 2003; 59: 793-799.</mixed-citation><mixed-citation xml:lang="en">Granberg D, Sundin A, Janson ET et al. Octreoscan in patients with bronchial carcinoid tumours. Clin Endocrinol (Oxf) 2003; 59: 793-799.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Srirajaskanthan R, Kayani I, Quigley AM et al. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DT-PA-octreotidescintigraphy. J NuclMed2010;51:875-882.</mixed-citation><mixed-citation xml:lang="en">Srirajaskanthan R, Kayani I, Quigley AM et al. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DT-PA-octreotidescintigraphy. J NuclMed2010;51:875-882.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Emilio Bombardieri, Valentina Ambrosini, Cumali Aktol-un, Richard P. Baum, Angelica Bishof-Delaloye, Silvana Del Vecchio, Lorenzo Maffioli, Luc Mortemans, Wim Oyen, Giovanna Pepe, Arturo Chiti111 In-pentetreotide scintigraphy: procedure guidelines for tumour imaging.</mixed-citation><mixed-citation xml:lang="en">Emilio Bombardieri, Valentina Ambrosini, Cumali Aktol-un, Richard P. Baum, Angelica Bishof-Delaloye, Silvana Del Vecchio, Lorenzo Maffioli, Luc Mortemans, Wim Oyen, Giovanna Pepe, Arturo Chiti111 In-pentetreotide scintigraphy: procedure guidelines for tumour imaging.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Babak Fallahi, Reyhaneh Manafi-Farid, Mohammad Eftekhari, Armaghan Fard-Esfahani, Alireza Emami-Ar-dekani, Parham Geramifar, Mehdi Akhlaghi, Amir Pejman HashemiTaheri, andDavood Beiki. Diagnostic Efficiency of 68Ga-DOTATATE PET/CT as Compared to 99mTc-Octreotide SPECT/CT and Conventional Morphologic Modalities in Neuroendocrine Tumors.</mixed-citation><mixed-citation xml:lang="en">Babak Fallahi, Reyhaneh Manafi-Farid, Mohammad Eftekhari, Armaghan Fard-Esfahani, Alireza Emami-Ar-dekani, Parham Geramifar, Mehdi Akhlaghi, Amir Pejman HashemiTaheri, andDavood Beiki. Diagnostic Efficiency of 68Ga-DOTATATE PET/CT as Compared to 99mTc-Octreotide SPECT/CT and Conventional Morphologic Modalities in Neuroendocrine Tumors.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Haslerud T. SPECT-CT in neuroendocrine tumors. In: Clinical Application of SPECT-CT. Ahmadzadehfar H, Biersack HJ (eds). Springer-Verlag Heidelberg, New York, London 2014: 87-110.</mixed-citation><mixed-citation xml:lang="en">Haslerud T. SPECT-CT in neuroendocrine tumors. In: Clinical Application of SPECT-CT. Ahmadzadehfar H, Biersack HJ (eds). Springer-Verlag Heidelberg, New York, London 2014: 87-110.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Brabander T, Kwekkeboom DJ, Feelders RA, Brouwers AH, Teunissen JJM. Nuclear Medicine Imaging of Neuroendocrine Tumors. In: Neuroendocrine tumors: A Multidisciplinary Approach. Papotti M, de Herder WW (eds). Front Horm Res. Basel, Karger2015; 44: 73-87.</mixed-citation><mixed-citation xml:lang="en">Brabander T, Kwekkeboom DJ, Feelders RA, Brouwers AH, Teunissen JJM. Nuclear Medicine Imaging of Neuroendocrine Tumors. In: Neuroendocrine tumors: A Multidisciplinary Approach. Papotti M, de Herder WW (eds). Front Horm Res. Basel, Karger2015; 44: 73-87.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Massimo Carlini Abdominal Neuroendocrine Tumors. DOI: 10.1007/978-88-470-3995-1.</mixed-citation><mixed-citation xml:lang="en">Massimo Carlini Abdominal Neuroendocrine Tumors. DOI: 10.1007/978-88-470-3995-1.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
